Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page displays the ClinicalTrials.gov record for the SITISVEAL study, including its design, eligibility criteria, locations, outcomes, and study documents, instead of an access-denied message.
    Difference
    60%
    Check dated 2026-11-08T04:26:08.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T01:19:08.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-25T01:25:11.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The site footer revision marker changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T01:06:27.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov revision label in the footer changed from v3.7.0 to v3.7.1; the page still displays a 403 error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-11T01:42:03.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content with an error message and the site header indicating an access restriction.
    Difference
    20%
    Check dated 2026-09-20T00:38:33.000Z thumbnail image

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.